Abstract: The present invention provides improved chlortetracycline-containing animal feed compositions and processes and apparatuses for their preparation. In certain embodiments, raw fermentation broth comprising chlortetracycline is divided into two portions. The first portion is mixed with a compound that complexes chlortetracycline. The second portion is acidified and the solids are removed. The acidified liquid is treated with a complexing agent to produced a chlortetracycline complex. The first and second portions thus treated are then mixed and the mixture is passed on to a filter press or other means for separation of the solids to produce a wet cake comprising complexed chlortetracycline. In alternative embodiments, the second portion may be acidified and filtered and admixed with the first portion prior to the complexing step. The resulting mixture is passed on to a filter press or other means for separation of the solids.
Abstract: The present invention teaches various femtosecond machining and drilling apparatus and processes for fabricating tools and the like from both traditional and non-traditional materials. Also described are novel tools such as scalpels, and nozzles fabricated from the apparatus and processes of the present invention. Likewise, the present invention may be utilized in both a novel propulsion system and the production of materials formed from nanometer sized particles and the like.
Type:
Grant
Filed:
March 5, 1998
Date of Patent:
December 3, 2002
Assignee:
Board of Regents, University of Nebraska-Lincoln
Abstract: The present invention relates to the fabrication of a boron carbide/boron semiconductor devices. The results suggest that with respect to the approximately 2 eV band gap pure boron material, 0.9 eV band gap boron carbide (B5C) acts as a p-type material. Both boron and boron carbide (B5C) thin films were fabricated from single source borane cage molecules using plasma enhanced chemical vapor deposition (PECVD). Epitaxial growth does not appear to be a requirement. We have doped boron carbide grown by plasma enhanced chemical vapor deposition. The source gas close-1,2-dicarbadecaborane (orthocarborane) was used to grow the boron carbide while nickelocene (Ni(C5H5)2) was used to introduce nickel into the growing film. The doping of nickel transformed a B5C material p-type relative to lightly doped n-type silicon to an n-type material. Both p-n heterojunction diodes and n-p heterojunction diodes with n- and p-type Si [1,1,1] respectively.
Type:
Grant
Filed:
December 16, 1999
Date of Patent:
August 27, 2002
Assignee:
Board of Regents, University of Nebraska-Lincoln
Abstract: Thioltransferase and derivatives thereof are provided. Methods of treating or preventing cataract formation comprising administering thioltransferase or a derivative thereof are also provided. Thioltransferase or derivatives thereof are also useful for treating or preventing diseases resulting from or associated with oxidative stress. Human lens thioltransferase and a DNA sequence encoding the same are also provided.
Type:
Grant
Filed:
September 29, 1998
Date of Patent:
April 30, 2002
Assignee:
Board of Regents University of Nebraska-Lincoln
Inventors:
Marjorie F. Lou, Nalini Raghavachari, Fengyu Qiao
Abstract: A method for treating neoplastic disease in animals including humans comprises administering a first composition comprising a TS inhibitor and a second composition comprising a nucleic acid-directed chemotherapeutic agent, and a composition for treating neoplastic disease in animals including humans comprises a first composition comprising a TS inhibitor and a second composition comprising a nucleic acid-directed chemotherapeutic agent. In a preferred embodiments, the TS inhibitor is a homo-oligomer of FdUMP, and the nucleic acid-directed chemotherapeutic agent is 5-FU or a pro-drug thereof. In a further aspect, compositions of a homo-oligonucleotide of 5-fluoro-2′-deoxyuridine-5′-O-monophosphate (FdUMP) with 5-fluorouracil exhibit a synergistic biological effect on neoplastic cells when compared to the activity of the individual components, the compositions being useful in the treatment of cancer in animals, including humans.
Abstract: A fiber reinforced composite material comprising a resin matrix and primary reinforcement fibers and further comprising secondary, smaller diameter, reinforcement fibers at one or more ply interfaces, or portion thereof, provides improved interlaminar toughness, strength, and delamination resistance without substantial reduction of in-plane properties and without substantial increase in weight. In one embodiment, the small fibers are attached to one side of a conventional prepreg prior to lamination. The small fibers are flexible and are expected to conform to the shape and distribution of the primary reinforcing fibers at the interface.
Type:
Grant
Filed:
December 1, 1998
Date of Patent:
July 24, 2001
Assignee:
Board of Regents, University of Nebraska-Lincoln